amglidia
ammtek - glibenclamide - sukkersyke - legemidler som brukes i diabetes - amglidia er angitt for behandling av neonatal diabetes mellitus, for bruk på nyfødte, spedbarn og barn. sulphonylureas som amglidia har vist seg å være effektiv hos pasienter med mutasjoner i gener som koder for β-celle atp-sensitive kalium kanal og kromosom 6q24-relaterte forbigående neonatal diabetes mellitus.
hydroxyzine orifarm 10 mg
orifarm generics a/s - hydroksyzinhydroklorid - tablett, filmdrasjert - 10 mg
hydroxyzine orifarm 25 mg
orifarm generics a/s - hydroksyzinhydroklorid - tablett, filmdrasjert - 25 mg
hydroxyzine orion 25 mg
orion corporation - espoo - hydroksyzinhydroklorid - tablett, filmdrasjert - 25 mg
hydroxyzine orion 10 mg
orion corporation - espoo - hydroksyzinhydroklorid - tablett, filmdrasjert - 10 mg
clindamycin navamedic 300 mg
navamedic asa - klindamycinfosfat - infusjonsvæske, oppløsning - 300 mg
clindamycin navamedic 600 mg
navamedic asa - klindamycinfosfat - infusjonsvæske, oppløsning - 600 mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
ketalar 10 mg/ ml
pfizer as - ketaminhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml
ketalar 50 mg/ ml
pfizer as - ketaminhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml